AnaptysBio reports Q1 results on May 15 with short sellers quietly adding pressure just as the stock trades near its lowest level in months.
The short interest angle is the standout setup heading into this print. Bears rebuilt their position sharply this week — short interest jumped roughly 8% over five days to 16.1% of the free float, reversing a month of gradual unwinding. The move is notable in context: short positions had drifted lower through most of April, but the spike on May 8–11 lands the SI back above levels seen for most of the prior six weeks. Borrow conditions give no squeeze pressure to offset this — cost to borrow runs at just 0.42%, effectively flat, and availability remains wide, meaning new shorts face little friction entering the stock. The ORTEX short score of 59.2 is consistent with a moderately bearish signal, though not extreme.
Options tell a diverging story. The put/call ratio hit 8.36 on Tuesday, well above its 20-day average of 5.1, but the z-score of 0.64 means the spike is within the recent range of volatility — this market has seen a PCR above 18 as recently as late April. The stock itself has had a rough few weeks: down 3.4% on Tuesday alone, 5.3% on the week, and 6.4% over the past month to close at $65.58. That price sits roughly 20% below the mean analyst target of $81.36, suggesting the Street still sees upside despite the weakness.
The analyst picture is one of diverging conviction. UBS cut its target from $90 to $60 in late April — a sharp 33% trim while keeping a Buy rating — signalling confidence in the story but materially lower near-term expectations. Barclays followed with a similar move, trimming from $79 to $63 while maintaining Overweight. By contrast, Leerink Partners raised its target from $66 to $85 around the same time, arguing the selloff was overdone. The bull case centres on royalty revenue from GSK-partnered assets, with analysts projecting potential royalties above $390 million annually from 2029, plus pipeline optionality in EoE and celiac disease. Bears counter that the pipeline is early-stage, revenue is still largely milestone-dependent, and competition in the target indications is intensifying.
Institutional ownership adds an interesting wrinkle. EcoR1 Capital holds a concentrated 27.4% of shares outstanding — an unusually large single-holder position that could amplify price moves in either direction after the release. CEO Dan Faga sold roughly $820,000 worth of shares in late March, spread across multiple transactions at prices between $57 and $65. The sales were modest relative to EcoR1's anchor position, but they were made at levels close to where the stock trades today.
The two prior confirmed earnings prints both saw the stock gain — up 4.2% the day after the March 2026 event and up 10.3% the day after the March 2025 event. Thursday's release will test whether those bullish reactions were product-driven or simply sentiment-driven, and whether the near-term royalty trajectory justifies a P/E of 29x after a month of multiple compression.
See the live data behind this article on ORTEX.
Open ANAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
